Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)

Trial Profile

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Influenza-immune-globulin-Emergent-BioSolutions (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Therapeutic Use
  • Acronyms INSIGHT 006
  • Most Recent Events

    • 30 Mar 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 30 Mar 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 11 Feb 2016 United Kingdom Clinical Research Network record mentions planned end date as 2 Jan 2017; kept as 1 Oct 2017 as per NCT record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top